Last updated: July 9, 2026
Gleevec (imatinib) is a mature oncology asset with limited near-term “IP-driven upside” in the US. Its patent estate and exclusivity have largely run through, and the global market is dominated by generics and licensed manufacturers. Investment relevance today is tied to (1) ongoing revenue support from branded cohorts in select geographies and payer mixes, (2) competitive durability versus oral multikinase alternatives, and (3) the credibility and timeline of next-generation product substitution (notably asciminib and other BCR-ABL competitors) that can reprice the treatment landscape.
What patents protect Gleevec (imatinib) and who holds the IP?
Short answer: Core protection for the original Gleevec product (composition of matter, formulations, and method-of-use claims for CML/Ph+ ALL) has largely expired in most markets; enforcement today is mainly about last-mile formulation/process patents (where still active in specific jurisdictions) and secondary patent estates around specific dosing, salt forms, and manufacturing methods.
Patent estate structure for imatinib (how the IP typically breaks down)
For small-molecule tyrosine kinase inhibitors like imatinib, patent portfolios generally include:
- Composition of matter (API and salt form)
- Pharmaceutical compositions/formulations (tablet/capsule, excipient systems, particle size, coatings)
- Method-of-use (indications such as chronic myeloid leukemia, Philadelphia chromosome-positive ALL, and specific response states)
- Manufacturing/process (crystallization conditions, polymorph control)
Who typically owns imatinib’s core IP
Historically, imatinib’s foundational IP traces to originator R&D entities and their patent filers and assignees tied to early development and registration for CML and Ph+ ALL. The business implication is that today’s “investment IP” is dominated by:
- the remaining life of secondary patents in specific countries, and
- litigation outcomes that can accelerate or delay generic competition.
How to think about “protectable upside” for Gleevec
- In the US, branded exclusivity is not the main driver now; generic availability is entrenched.
- In Europe and emerging markets, “last-mile” patent and regulatory discontinuities can still affect pricing, but the asset’s global competitive pressure is already severe.
(This section is intentionally structured for patent estate mapping; a jurisdiction-by-jurisdiction table requires specific Orange Book entries and active patent numbers, which are not included in the provided prompt.)
When does Gleevec (imatinib) lose exclusivity and what does that mean for pricing?
Short answer: Gleevec entered generic competition years ago in major markets. Exclusivity loss in the US and most OECD geographies is effectively already realized; price is now a function of generic supply, reimbursement dynamics, and contracting behavior rather than patent cliffs.
Exclusivity and generic timeline impact
- After loss of exclusivity, branded pricing in US and many EU markets tends to normalize toward generic parity, subject to payer contracting and patient acquisition retention.
- The branded asset can still hold share in:
- formulary exceptions,
- brand loyalty and tolerability history,
- contract-specific renewals,
- specific patient subpopulations where switching risk is managed.
Investment implication
For an investor, the “exclusivity question” in 2026 is less about launch risk and more about:
- the persistence of any residual branded premium,
- the speed at which generic manufacturers discount,
- the degree of supply concentration among generics and biosupply chains.
What is the Orange Book status of Gleevec (imatinib) and how does it affect generic entry risk?
Short answer: Gleevec’s Orange Book-driven launch barriers are largely moot for new generic entry because multiple generics and authorized versions exist. The remaining impact is about any still-listed secondary patents and whether they were carved out in settlements.
Business meaning of Orange Book status
- For investors, Orange Book status affects:
- Paragraph IV and other challenge strategy windows (now mostly historical),
- generic launch date expectations,
- the durability of branded tender leverage.
Generic entry risk now
- If additional secondary patents exist in the relevant listing(s), the practical risk is not “whether generics can launch” but:
- whether launches are delayed for specific strengths/dosage forms,
- whether there is ongoing litigation that influences price.
(A precise Orange Book table with listed patents, expiration dates, and active/inactive status is not provided in the prompt.)
How many patents cover Gleevec and what types of claims are left (formulation, method-of-use, or manufacturing)?
Short answer: The remaining patent relevance is typically skewed toward secondary formulation/manufacturing claims, and method-of-use claims that may still apply to narrower patient-defined scenarios in select jurisdictions, but most claims tied to broad initial indications have already expired.
What “counts” in investment risk models
- Scope overlap with generic ANDA manufacturing and labeling.
- Claim survivability through obviousness, enablement, and novelty challenges.
- Jurisdiction-specific enforcement and practical willingness to litigate against entrenched generics.
Where formulation patents matter most
Formulation patents matter when:
- generics attempt to use a different dissolution profile or excipient system,
- the brand maintains a differentiated PK or stability profile that payers value.
What patent litigation affects Gleevec (imatinib) and which settlements changed the generic landscape?
Short answer: Gleevec historically faced US generic challenges and litigation that resulted in settlements and staggered entry schedules for specific generics and strengths. Today, the critical question is not “ongoing litigation” but the extent to which earlier settlements removed remaining barriers.
Investment takeaway from long-running settlements
- Settlements often lock in a “generic supply schedule” and can become a de facto market structure driver.
- Once multiple manufacturers have launched and diversified supply, subsequent litigation has limited pricing impact.
(A current, case-by-case litigation docket list is not present in the prompt. Without that, a complete litigation table cannot be produced.)
What formulations are protected for Gleevec (imatinib) and how do they map to generic substitutability?
Short answer: Original Gleevec is an oral solid dose; the key risk for branded pricing is generic substitutability on bioequivalence and formulation equivalence. Any remaining formulation-specific barriers in particular jurisdictions can slow substitution for certain strengths, but not the entire market.
What investors should model
- Strength-by-strength generic penetration (100 mg, 400 mg, etc. in branded markets).
- Bioequivalence and dissolution compliance in jurisdictions with stricter enforcement.
- Tendering structures that prefer “lowest net price” versus “brand continuity.”
How does Gleevec compare with asciminib and other BCR-ABL therapies on investable fundamentals?
Short answer: Competing BCR-ABL assets shape future revenue potential more than residual patent life. Asciminib (SCemblix) and other TKIs reduce the long-term growth runway for older TKIs and can reallocate treated patient share over time.
Competitive positioning
- Gleevec (imatinib): established efficacy with entrenched use patterns; pricing pressure is structurally high due to generics.
- Second-/third-line TKIs: often priced at premium levels and used to optimize efficacy, resistance management, or tolerability.
- Asciminib: targets different mechanistic space within BCR-ABL biology and can shift sequencing.
Investment implication
- The valuation sensitivity shifts from “IP clock” to “treatment sequencing and guideline adherence.”
- Even when Gleevec holds share, the growth rate is capped by:
- generic price compression,
- substitution to newer agents for relapsed/refractory or specific molecular profiles,
- payer utilization management.
(A full head-to-head commercial dataset requires revenue and share details not included in the prompt.)
What is the commercial exposure of Gleevec (imatinib) by geography and payer model?
Short answer: Commercial exposure is now primarily tied to the residual branded premium (where present) and the pace of generic price compression, which differs by country, tender structure, and reimbursement.
Geographic investment lens
- US: generics drive economics; branded share depends on contracts and formulary exceptions.
- EU5 and Canada: similar dynamics, moderated by national tender systems.
- Emerging markets: can retain more brand presence longer, but with higher regulatory and procurement variability.
What to model in an investment case
- Net price and reimbursement evolution vs generic benchmarks.
- Generic channel concentration (risk of margin collapse when multiple suppliers compete aggressively).
- Contract renewal cycles and wholesaler behavior.
How strong is the patent estate for Gleevec (imatinib) versus generic pressure?
Short answer: The estate strength is not a near-term defense engine in major markets; it is a localized defense factor where secondary patents or enforcement remain active.
Patent strength framework for mature TKIs
For imatinib, the most relevant “strength metrics” are:
- whether any secondary patents remain enforceable for relevant dosage forms,
- whether claim scope blocks ANDA manufacturing/labeling,
- whether there is evidence of continued payer or prescriber differentiation based on formulation.
Practical market conclusion
Generic pressure is the dominant determinant of gross margin now; patent strength is secondary.
What generic entry risks exist for Gleevec (imatinib) in 2026?
Short answer: Entry risk is low in the sense of “new competitors can launch.” The risk that matters is:
- additional generic erosion via new supply entrants,
- periodic margin drops when contracts reset,
- potential “last-mile” delays from remaining secondary patents in select jurisdictions.
Where entry can still shift economics
- Regions that still have partial branded retention.
- Specific strengths or packaging formats where substitution lags.
How do investors underwrite Gleevec revenue in a generics-first world?
Short answer: Underwriting focuses on:
- residual branded economics,
- generic competition intensity,
- sequencing changes to newer therapies,
- channel stability.
Core underwriting model components
- Residual branded volume: prescription share where brand still carries weight.
- Price deck: expected trajectory vs generic baskets.
- Rebates/discounting: payer-specific dynamics that can change net price quickly.
- Sequencing effects: share transfer to asciminib and other modern BCR-ABL agents.
Key Takeaways
- Gleevec’s near-term investment story is not driven by blockbuster IP expansion; it is driven by mature generics economics and treatment sequencing pressures from newer BCR-ABL therapies.
- Patent and Orange Book timing are largely historical in the US; any remaining patent impact is localized to secondary claims in specific jurisdictions.
- The investable variable is residual net price and branded share persistence versus generic channel dynamics.
- Competitive replacement risk is managed through guideline sequencing and mechanistic differentiation of next-generation therapies, which can cap upside even if Gleevec retains durability.
FAQs
1) Is Gleevec still protected by patents in the US?
Core Gleevec exclusivity has largely run; only localized secondary patents, if any remain, can affect narrow aspects of generic substitutability.
2) Can generics of imatinib legally substitute for Gleevec without switching restrictions?
In most major markets, substitutability is typical because bioequivalence frameworks permit interchangeability, subject to national payer rules and formularies.
3) Does Gleevec have any remaining formulation advantages versus generic imatinib?
Any advantages depend on jurisdiction-specific formulation differentiation and whether prescribers/payers treat the brand as clinically or operationally distinct.
4) How does asciminib affect the long-term outlook for imatinib use?
Asciminib can shift patient sequencing and reduce future demand growth for older TKIs, especially in relapsed settings or molecularly defined subgroups.
5) What is the main driver of Gleevec margins today?
Generic price compression and payer contracting behavior dominate; residual IP effects are secondary.
References (APA)
No sources were provided in the prompt to cite for Gleevec’s Orange Book listings, specific patent numbers, litigation docket outcomes, or current FDA regulatory status.
